Xcopri is not a benzodiazepine. It is an antiepileptic drug classified as a carbamate derivative, approved for treating focal (partial-onset) seizures in adults. The confusion is understandable because Xcopri does interact with some of the same brain chemistry that benzodiazepines target, but it does so in a fundamentally different way.
How Xcopri Differs From Benzodiazepines
Both Xcopri (cenobamate) and benzodiazepines like diazepam or clonazepam enhance the activity of GABA, a brain chemical that calms nerve signaling. That shared trait is likely why the question comes up. But they work at completely different spots on the GABA receptor, and this distinction matters.
Benzodiazepines latch onto a specific binding site on the GABA receptor. Xcopri binds to a separate, independent site. Researchers confirmed this by testing whether flumazenil, a drug that blocks and reverses benzodiazepine effects, had any impact on Xcopri’s activity. It did not. Xcopri also failed to displace benzodiazepine molecules from their binding site in lab studies. In pharmacological terms, Xcopri is a positive allosteric modulator of GABA receptors at a non-benzodiazepine site.
Beyond GABA, Xcopri has a second mechanism that benzodiazepines lack entirely: it blocks voltage-gated sodium channels, reducing the repetitive firing of overactive neurons. This dual mechanism is part of what makes it distinct as a seizure medication.
What Xcopri Is Used For
Xcopri received FDA approval in late 2019 specifically for partial-onset seizures in adults. These are seizures that start in one area of the brain, though they can sometimes spread. It is used as an add-on therapy alongside other seizure medications, not typically as a standalone treatment.
The drug is taken once daily and requires a slow, gradual dose increase over about 11 weeks. Patients start at 12.5 mg and move up in two-week steps: 25 mg, then 50 mg, 100 mg, 150 mg, and finally 200 mg as the standard maintenance dose. Some people may go as high as 400 mg daily if needed, increasing by 50 mg every two weeks. This slow titration exists largely because of a serious skin reaction risk (called DRESS) that was identified during clinical trials and is more likely with rapid dose increases.
Controlled Substance Status
Xcopri is a Schedule V controlled substance, the lowest category of controlled drugs under federal law. The DEA placed it in this category in March 2020, recognizing it has some potential for dependence but significantly less than drugs in higher schedules. For comparison, benzodiazepines are Schedule IV, one level higher in terms of abuse and dependence risk. Common Schedule V drugs include certain cough preparations with small amounts of codeine.
The Schedule V classification means your pharmacy will track dispensing, but prescribing and refill restrictions are less stringent than those for benzodiazepines.
Key Safety Considerations
Xcopri carries a few notable warnings that set it apart from many other seizure medications. The most distinctive is its effect on heart rhythm. It can cause QT shortening, a change in the electrical timing of the heartbeat. People with a rare inherited condition called familial short QT syndrome should not take it. Symptoms of a heart rhythm problem can include dizziness, fainting, or a fast or irregular heartbeat that persists.
The DRESS reaction, a severe immune response involving skin rash, fever, and organ involvement, is another serious risk. It typically emerges during the first weeks of treatment, which is why the titration schedule is so gradual. Skipping the slow ramp-up increases the likelihood of this reaction.
Xcopri also affects how your liver processes other medications. It increases the activity of one liver enzyme pathway while decreasing another, which can raise or lower the blood levels of drugs you take alongside it. This is particularly relevant for people on hormonal birth control, certain cancer therapies, or other medications broken down by these same enzyme systems. Your prescriber will need to review your full medication list before starting Xcopri and may need to adjust doses of other drugs.
Why the Confusion With Benzodiazepines
The question likely arises because Xcopri’s GABA-enhancing effects can produce some side effects that overlap with benzodiazepines: drowsiness, dizziness, and fatigue are common with both. Its controlled substance status may also raise flags for people who associate that label with drugs like benzodiazepines or opioids. But its chemical structure (a carbamate, not a benzodiazepine), its binding site on the GABA receptor, its sodium channel activity, and its clinical use as an epilepsy drug all place it in a completely different pharmacological category.